Could a clotting booster cut blood loss in ICU patients?
NCT ID NCT04555785
First seen Jun 12, 2026 · Last updated Jun 12, 2026
Summary
This study looks at whether adding a drug called Wilate (a von Willebrand factor concentrate) to standard platelet transfusions can reduce bleeding and the need for more blood products in intensive care patients. About 120 adults who need platelets during or after surgery will be randomly assigned to get Wilate or a placebo. The goal is to see if this combination leads to less blood loss and better outcomes.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BLEEDING are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
University Hospital Basel
RECRUITINGBasel, 4031, Switzerland
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.